Standard chemoradiotherapy with concurrent and adjuvant camrelizumab in patients with high risk nasopharyngeal carcinoma: multicentre, randomised, open label, phase 3 trial

Journal:

The BMJ

Published:

2026-02-10

DOI:

10.1136/bmj-2025-085863

Affiliations:

14

Authors:

30

Go to article

Institutions	Authors	Share
Sun Yat-sen University Cancer Center (SYSUCC), SYSU, China	7.100000	0.24
State Key Laboratory of Oncology in South China, SYSUCC, China	7.100000	0.24
The Fifth Affiliated Hospital, SYSU, China	5.300000	0.18
Zhongshan City People's Hospital, China	2.000000	0.07
Wuzhou Red Cross Hospital, China	2.000000	0.07
Tongji Hospital (TJH), HUST, China	2.000000	0.07
Sun Yat-sen Memorial Hospital, SYSU, China	2.000000	0.07
Southern Medical University (SMU), China	1.000000	0.03
The First Affiliated Hospital of Nanchang University, China	1.000000	0.03
Dongguan People's Hospital, China	0.500000	0.02

Interested in Clinical Sciences?